Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis
Authors:
- N. V. GrygorievaNGN. V. Grygorieva
- V. M. KovalenkoVKV. M. Kovalenko
- M. O. КorzhMКM. O. Кorzh
- M. D. TronkoMTM. D. Tronko
- I. Yu. GolovachIGI. Yu. Golovach
- N. V. DedukhNDN. V. Dedukh
- D. G. RekalovDRD. G. Rekalov
- S. S. StrafunSSS. S. Strafun
- S. I. SmiyanSSS. I. Smiyan
- O. A. GolubovskaOGO. A. Golubovska
- Ya.O. DziublykYDYa.O. Dziublyk
- N. V. KharchenkoNKN. V. Kharchenko
- 24 February 2025
- journal article
- practice guideline
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 20 (1) , 1-16
Abstract
Introduction Glucocorticoid-induced osteoporosis (GIOP) is a bone metabolic disorder caused by glucocorticoid (GC) use. It is one of the leading causes of secondary osteoporosis, increasing the risk of low-energy fractures, disability, and mortality. Although limited studies on GIOP epidemiology and treatment have been conducted in Ukraine, there were no national guidelines for its management. The aim was to create national guideline for the GIOP diagnosis, prevention, and treatment based on a comprehensive review of modern literature to enhance awareness within Ukraine’s medical community, improve disease management, and reduce its socio-economic impact. Materials and methods An Expert Group comprising 18 leading Ukrainian scientists from various fields was created for guideline development. A review of modern literature on GIOP epidemiology, risk factors, diagnosis, prevention, treatment, and monitoring was conducted. Evidence synthesis followed the GRADE methodology, and the quality of recommendations was critically evaluated using the AGREE II tool. Results The guideline comprises 12 statements covering GIOP screening, diagnosis, prevention, and treatment. We highlight the need to raise awareness among healthcare providers and patients about the potential effects of GC therapy. Also, we outline approaches to clinical assessment of osteoporotic fracture risk in GC users and detail diagnostic and therapeutic methods currently available in Ukraine for managing GIOP. Conclusion The first Ukrainian national GIOP guideline is critical for healthcare providers across specialities. Endorsed by the Board of the Ukrainian Association of Osteoporosis, it is recommended for use in routine clinical practice to enhance patient outcomes and mitigate the disease’s impact.Keywords
This publication has 162 references indexed in Scilit:
- A family history of fracture and fracture risk: a meta-analysisBone, 2004
- A meta-analysis of previous fracture and subsequent fracture riskBone, 2004
- A Meta-Analysis of Prior Corticosteroid Use and Fracture RiskJournal of Bone and Mineral Research, 2004
- Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapyArthritis & Rheumatism, 2003
- The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysisOsteoporosis International, 2002
- Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trialArthritis & Rheumatism, 2001
- Use of Oral Corticosteroids and Risk of FracturesJournal of Bone and Mineral Research, 2000
- Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid-Induced Osteoporosis in Men and Women: A Randomized TrialJournal of Bone and Mineral Research, 2000
- Risedronate therapy prevents corticosteroid-induced bone loss : A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyArthritis & Rheumatism, 1999
- Alendronate for the Prevention and Treatment of Glucocorticoid-Induced OsteoporosisNew England Journal of Medicine, 1998